NanoBio Corporation Awarded New Patent Covering its Nanoemulsion-Based Anti-Infective Product Candidate for the Treatment of Cold Sores
ANN ARBOR, Mich.--(BUSINESS WIRE)--NanoBio Corporation announced today that it has been awarded a seventh U.S. patent covering its novel nanoemulsion technology. The new claims encompass methods of treating Herpes Simplex I infections, including herpes labialis (commonly referred to as cold sores), using NanoBio’s proprietary anti-infective nanoemulsion product candidates.